Capital Advisors Inc. OK raised its stake in Abbott Laboratories (NYSE:ABT) by 0.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,278 shares of the healthcare product maker’s stock after buying an additional 1 shares during the period. Capital Advisors Inc. OK’s holdings in Abbott Laboratories were worth $522,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Parasol Investment Management LLC increased its stake in shares of Abbott Laboratories by 30.5% in the second quarter. Parasol Investment Management LLC now owns 2,570 shares of the healthcare product maker’s stock worth $101,000 after buying an additional 600 shares during the last quarter. SeaBridge Investment Advisors LLC increased its stake in shares of Abbott Laboratories by 10.6% in the second quarter. SeaBridge Investment Advisors LLC now owns 2,875 shares of the healthcare product maker’s stock worth $113,000 after buying an additional 275 shares during the last quarter. CapWealth Advisors LLC increased its stake in shares of Abbott Laboratories by 15.2% in the first quarter. CapWealth Advisors LLC now owns 3,038 shares of the healthcare product maker’s stock worth $127,000 after buying an additional 400 shares during the last quarter. Delta Asset Management LLC TN increased its stake in shares of Abbott Laboratories by 2.8% in the second quarter. Delta Asset Management LLC TN now owns 3,695 shares of the healthcare product maker’s stock worth $146,000 after buying an additional 100 shares during the last quarter. Finally, Cribstone Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the second quarter worth about $150,000. 73.03% of the stock is owned by institutional investors.
Abbott Laboratories (NYSE:ABT) traded down 0.22% during trading on Wednesday, hitting $41.49. 2,093,391 shares of the company traded hands. The stock has a market capitalization of $60.99 billion, a PE ratio of 27.39 and a beta of 0.82. The company’s 50 day moving average is $43.26 and its 200-day moving average is $41.17. Abbott Laboratories has a 52 week low of $36.00 and a 52 week high of $46.38.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.02. The company earned $5.30 billion during the quarter, compared to analyst estimates of $5.24 billion. Abbott Laboratories had a net margin of 11.08% and a return on equity of 15.11%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.52 earnings per share.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Wednesday, October 12th. This represents a $1.04 annualized dividend and a yield of 2.50%. Abbott Laboratories’s dividend payout ratio (DPR) is 68.87%.
A number of equities research analysts have issued reports on ABT shares. Barclays PLC reaffirmed an “overweight” rating and issued a $48.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, July 12th. Bank of America Corp. reiterated a “buy” rating and issued a $50.00 target price on shares of Abbott Laboratories in a research note on Friday, August 12th. TheStreet upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, August 22nd. Credit Suisse Group AG reiterated a “buy” rating on shares of Abbott Laboratories in a research note on Wednesday, June 8th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 target price on shares of Abbott Laboratories in a research note on Monday. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $47.02.
In other news, Chairman Miles D. White purchased 242,547 shares of the stock in a transaction on Monday, July 25th. The shares were acquired at an average price of $43.18 per share, with a total value of $10,473,179.46. Following the completion of the acquisition, the chairman now directly owns 2,010,517 shares of the company’s stock, valued at $86,814,124.06. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Hubert L. Allen sold 3,400 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $37.14, for a total transaction of $126,276.00. Following the transaction, the executive vice president now directly owns 91,857 shares in the company, valued at approximately $3,411,568.98. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.